2 results
Approved WMOWill not start
Primary: To determine the safety and tolerability of TCAD administered orally to immunocompromised patients diagnosed with influenza ASecondary: To assess the antiviral effect, the speed of symptom resolution, and the influenza complication rate of…
Approved WMOCompleted
Primary:Determine the MTD and/or RDE(s) of ABL001:* As a single agent for CML CP and AP patients* In combination with either nilotinib or imatinib or dasatinib in CML CP and AP patients* As a single agent for CML BP patients and Ph+ ALL…